plans to expand?

any news lately?

 

I would guess no time soon. They did a very selective limited expansion in high growth areas and added about a dozen reps. Anything beyond that would be beyond crazy in this market.

 

Soon to be a contraction (layoff) based on pathetic sales trends and huge losses...

 

Downsizing would be a GOOD thing for the health of the company. We don't need 131 reps and we didn't need 118 before that. Could easily get by with half that. And ax the Health System whatever they're called reps. Don't need them either. While Joe's at it, he could also get rid of the Area Sales Managers. Don't need that extra layer of management of non revenue producers.

 

This company is hell bent on expanding because we are being lead by a big pharma exec. Nevermind the declining market they will make the mistakes of every other big pharma company that ZS consults for. They follow an old and outdated sales model in a market that should not be seeing expansion! When will these companies learn ?

 

bingo!

 

There is a lot of business to be had in the hospital space. It is a long process and takes time to get contracts and then pull through but in order to compete at a higher level we will need to garner that business! Hospital reps are necessary in order to take this company to the next level. I don't think a downsizing is necessary but certainly no more expansion! I'm sure ZS is still all about share of voice and reach and frequency like they have always been! They are the downfall of every good pharma company!

 

OxyC, will be fully generic by then....

 

Net product revenues for Xtampza ER for the 2017 Quarter were $12.0 million ($7.6 million without the one-time $4.4 million increase)

You guys are killing it!

2 Billion in Oxy sales and you are up to 12M!

Net product revenues for Xtampza ER for the 2017 Quarter were $12.0 million ($7.6 million without the one-time $4.4 million increase)

 

Net product revenues for Xtampza ER for the 2017 Quarter were $12.0 million ($7.6 million without the one-time $4.4 million increase)

You guys are killing it!

2 Billion in Oxy sales and you are up to 12M!

Net product revenues for Xtampza ER for the 2017 Quarter were $12.0 million ($7.6 million without the one-time $4.4 million increase)

 

Just keep watching joker! This company is gaining momentum and is poised for great things! Unlike Purdue that is heading the exact opposite direction!

 

Investors; in ten more years we will break even and pay you 1$.

 

Again, we have more than just beeswax in our patented technology. Go away

 

Your an idiot. The patent you speak of is on potassium chloride with beeswax. Our patent is on oxycodone with beeswax, carnauba wax, and fatty acids.

Try again. Go be a b*tch somewhere else.